Abstract Many studies focused on the discovery of novel biomarkers for the diagnosis and treatment of disease states are facilitated by mass spectrometry-based technology. HPLC coupled to mass spectrometry is widely used; miniaturization of this technique using nano-liquid chromatography (LC)-mass spectrometry (MS) usually results in better sensitivity, but is associated with limited repeatability. The recent introduction of chip-based technology has significantly improved the stability of nano-LC-MS, but no substantial studies to verify this have been performed. To evaluate the temporal repeatability of chip-based nano-LC-MS analyses, N-glycans released from a serum sample were repeatedly analyzed using nLC-PGC-chip-TOF-MS on three non-consecutive days. With an average inter-day coefficient of variation of 4 %, determined on log 10 -transformed integrals, the repeatability of the system is very high. Overall, chip-based nano-LC-MS appears to be a highly stable technology, which is suitable for the profiling of large numbers of clinical samples for biomarker discovery.
Introduction
The development of biomarkers is important for the diagnosis and treatment of disease states and may serve several purposes, including the early detection of diseases (e.g., [1] ), differentiation between disease categories [2] , and to predict and monitor the response to treatment [3, 4] . Therefore, numerous studies are being conducted aiming to identify such markers for various diseases at different levels in biology, including genomics [5] , proteomics [6] , metabolomics [7] , and glycomics [8, 9] .
The technology used in proteomics-, metabolomics-, and glycomics-based studies often comprises liquid chromatography (LC) coupled to mass spectrometry (MS). This strategy is widely accepted and has resulted in tremendous progress in our understanding of biochemical processes. Nano-scale LC-MS has several potential advantages such as the higher sensitivity, efficiency and resolution in separation, selectivity, and shorter analysis time. The use of nano-LC-MS is also associated with some limitations, including the relatively high LC back pressure due to smaller particles for separation, lower stability of the LC gradient, and most importantly, decreased stability of the electrospray ionization process resulting in less consistent data. This has resulted in the somewhat slower adoption of nano-LC-MS in the field of biomarker discovery.
Recent technological developments, including but not limited to the introduction of microfluidic chip-based LC-MS, have significantly improved repeatability of nano-LC-MS analyses, both with respect to retention time and spray conditions. These developments allow the use of nano-LC-MS for the determination of compounds associated with a disease as suitable biomarkers for the clinical setting. Our group was the first to introduce chip-based nano-LC coupled to nano-ESI-TOF-MS for the analysis of Nglycans derived from human serum [10] [11] [12] and, more recently, blood [13] .
Good stability and repeatability of the analytical system are essential for the development of clinical biomarkers [14] . However, the suitability of the microfluidic chipbased nano-LC-MS technology has not been rigorously evaluated for use in large biomarker studies that span several days needed to analyze a large number of samples. In this study, we evaluated the temporal stability of the nLCchip-TOF instrument as an analytical tool for the identification and validation of glycan biomarker candidates. N-Glycans were released from one standard serum sample and purified using porous graphitized carbon (PGC) solidphase extraction (SPE). Stability of the nLC-chip-TOF-MS was assessed by the repeated analysis of a single sample over a period of three non-consecutive days.
Materials and methods
The methods used are described briefly here; more details of materials and methods can be found in the Electronic supplementary material.
N-Glycan sample preparation N-Glycans were released from the proteins in 50 μL of serum standard (Sigma-Aldrich, St. Louis, MO) as previously described [15] . Briefly, proteins were denatured, and N-glycans were enzymatically released in a microwave. Graphitized carbon SPE was used to purify the N-glycans as previously described [15] . The sample was dried in vacuo prior to analysis.
Study design
The dry N-glycan sample was reconstituted in 225 μL of water and transferred to an injection vial for analysis; 1 μL of sample was used for injection. The same N-glycan sample was used for all 3 days and stored at −80°C between the days. The N-glycan sample was analyzed continuously throughout a day with intermittent blanks on three nonconsecutive days. On each day, we continuously injected 1 μL of sample as long as the instrument allowed during daytime in a real-life setting; thus, the number of samples analyzed varied by day: Twelve analyses were performed on day 1, 22 analyses were performed on day 2, and 17 analyses were performed on day 3; the analyses on days 1 and 2 were performed on a previously used chip with approximately 300 h of operation, while for the analyses on day 3, a new analytical chip was used.
nHPLC-chip-TOF-MS analysis N-Glycans were analyzed using an Agilent nanoHPLCchip-TOF-MS, in which a PGC chip II (Agilent Technologies, Santa Clara, CA) packed with porous graphitized carbon was used. Upon injection, the sample was loaded onto the enrichment column and subsequently separated on the analytical column using a gradient of 3 % acetonitrile (ACN) with 0.5 % formic acid (FA) (solvent A) to 90 % ACN with 0.5 % FA (solvent B). The mass spectrometer was operated in positive mode.
Data analysis and statistics
Data analysis was performed using Masshunter® qualitative analysis according to Hua et al. [16] with modifications. Data were loaded into Masshunter® qualitative analysis, and glycan features were identified and integrated using the Molecular Feature Extractor algorithm. A retrosynthetic theoretical glycan library [17] containing 331 possible Nglycan compositions was used for glycan identification. For statistical analysis, the integral values were log 10 transformed to reduce the influence of extreme values to meet the normality assumption. Patterns in total glycan area and the proportion of non-detectables over time were evaluated graphically as was the relationship with the proportion of non-detectables and area values. Coefficients of variance (CVs) were calculated to assess inter-and intra-day variability. All data are reported as mean ± SD unless specified otherwise.
Results N-Glycans from human serum, which consist of hexoses (H), N-acetylhexosamines (N), fucoses (F), and Nacetylneuraminic acid (S), were separated, identified, and quantified using nLC-PGC-chip-TOF-MS. To separate the glycans, a PGC (5 μ) stationary phase was used, which was previously shown to result in very good glycan separation [18] . It was chosen to leave the reducing end of the glycans intact, which results in the chromatographic separation of the anomers on the PGC stationary phase.
The experiments were performed on three nonconsecutive days over a 10-day period. The first two days were performed using one chip, while the third day was performed using a different LC chip to determine the variations between microchips. The stability of the system as well as the separation of isomers is demonstrated in Fig. 1 The experiments provide an opportunity to determine the consistency of the glycan signals in the nano-LC-MS method. Figure 2 illustrates the relationship between the proportion of the glycans not detected and the log of the mean peak area. Glycan compositions with absolute intensities above 10 5 (log 5 with log 8 maximum) are observed in every spectra. Mean log peak areas below 4.5 are observed in about 50 % of the chromatograms, while those below 4.0 are observed in less than 20 % of the chromatogram. The results suggest a dynamic range of nearly four orders of magnitude (log 4 to log 8) for this method for the abundant peaks for consistent detection, while those near or less than log 4 are not consistently observed.
To evaluate the temporal stability of the method, the summed area of all glycan signals in each run was determined in sequence over the 3-day period (Fig. 3) . The overall glycan areas varied little within a day; however, slightly lower glycan abundances were observed on day 3 relative to day 1 and 2 (5.76×10 7 compared to 1.40×10 8 and 1.62×10 8 for days 3, 1, and 2, respectively). The drop in intensities is likely due to the performance of the new chip.
Day 1 and day 2 were performed with the same chip, while a different chip was used on day 3. Another potential reason for the decrease in the intensities for day 3 may be degradation of the oligosaccharides or absorption onto the vial surface. However, both are gradual processes that are expected to occur across the 3 days. The first 2 days are relatively constant, while the drop is largest in day 3 suggesting that the decrease is intrinsic to the chip and not due to sample loss. These experiments suggest that for consistency, particularly in biomarker studies, all samples should be performed on the same chip.
We further evaluated the stability of the nLC-chip-TOF instrument at the level of individual glycan compositions. Because this study is focused on repeatability, estimating or "imputing" missing values could affect the results. We therefore limited our analyses to the glycan compositions that were identified in all runs for each day. All glycan compositions that were not included for further data analysis were of low abundance, with integrals at an average of 3.5× 10 −4 relative to the highest glycan, as discussed previously.
The intra-day variability was then assessed using 63, 58, and Fig. 3 Repeatability of the analysis of serum-derived Nglycans using nLC-PGC-chip-TOF-MS. Each dot represents a total glycan area of all glycans in each run of the 3 days. Glycan areas are on log 10 scale; day 1 and day 2 were run on a chip with over 300 h of operation, while day 3 was run on a new chip. Day 1 is represented by blue dots, day 2 by red dots, and day 3 by black dots 57 glycan compositions that were consistently detected on day 1, 2, and 3, respectively. Using these glycans, the correlations in peak areas were calculated across runs within a day. For the correlation coefficients ranging from 0.90 to 0.99 for day 1, 0.70-0.99 for day 2, and 0.96-0.99 for day 3, exhibiting excellent within-day variability is generally very good. The lowest variation was obtained on day 3, when the new chip was used.
To evaluate the inter-day and intra-day repeatability of the instrument with respect to quantitation, we examined the areas of the 50 glycan compositions (listed in the Electronic supplementary material, Table S1 ) that were consistently detected in all 51 analyses performed throughout all 3 days. The coefficients of variation of the log 10 -transformed areas were calculated within a day and across days. The CVs were generally very small, with an average intra-day CV of 2.1± 1.7 % and average inter-day CV of 3.9±1.4 %. Additionally, the inter-and intra-day CVs declined as the mean intensity level increased (i.e., lower abundance compounds were more variable across runs); however, all CVs were less than 4 %. The results indicate excellent repeatability of the glycan quantitation using nLC-chip-TOF instrumentation even for low-abundance glycan compositions. We calculated the correlations for glycan compositions between day 1 and 2, day 1 and 3, and day 2 and 3 (Electronic supplementary material, Table S2 ). Interestingly, the glycan correlation between days 1 and 3 and between days 2 and 3 was much larger than that between days 1 and 2, indicating that the lower intensities observed on day 3 did not alter the glycosylation patterns.
Discussion
For biomarker discovery and development, it is essential to have a stable analytical platform. To our best knowledge, this study represents the first comprehensive analysis of the temporal stability of nano-LC-chip-TOF-MS for the profiling of N-glycans.
The repeatability of the method was excellent, with the average intra-day CV of 2.1±1.7 % and average inter-day CV of 3.9±1.4 %. While it was observed that the incidence of detection of a certain glycan depends on its abundance, the overall glycan integration did not depend on the number of glycans detected in a given sample. These results indicate that shifts in total abundances of a run do not necessarily affect the general N-glycan profile. Variation appears to occur primarily between days, when the chip is removed and reinserted, and when a new chip is used. When a chip is removed and reinserted, the ionization environment within the source may alter slightly but sufficiently to affect the total ion abundances.
Although the repeatability was generally excellent, slightly better performance was obtained on day 3, where a new chip was used. The new column resulted in slightly more consistent retention times compared to the other 2 days where the chip had already logged hundreds of hours. In sample sets where hundreds of samples are analyzed, a single chip may be sufficient to perform the analysis, while samples that number in the thousand may require some variation in the strategy so that variability between the beginning and the end can be minimized.
While we showed high analytical repeatability of the nLC-chip-TOF-MS, there are other technical aspects that could influence the success of biomarker discovery studies. These include the effects of sample preparation itself, as well as storage of the samples prior to, during, and after sample preparation [19] . These aspects, which are applicable not only to glycomics but also other "omics" such as proteomics or metabolomics in which mass spectrometry is applied, should be taken into account in design and interpretation of MS-based glycomics studies for biomarker discovery. We have performed systematic studies to determine the effects of sample preparation on the analytical repeatability using MALDI-FTICR-MS [15] and optimized the procedure for N-glycan release and purification from serum accordingly.
In conclusion, the repeatability of N-glycan profiles as analyzed by our platform was shown to be very high even when a combination of "old" and "new" chips is used. This study indicates that chip-based nano-LC-MS technology is a very stable technology, which is suitable for biomarker discovery studies.
